The efficacy of adalimumab in the treatment of uveitis
DOI:
https://doi.org/10.33448/rsd-v13i2.44915Keywords:
Uveitis; Adalimumab; Corticosteroids; Inflammation.Abstract
Uveitis is inflammation of the uveal tract. The main manifestations are ocular hyperemia, photophobia, ocular pain, blurred vision, irregular pupil and inflammatory nodules on the anterior surface of the iris. Currently, the treatment of uveitis is associated with the use of corticosteroids. Adalimumab (ADA) is a full-length human monoclonal antibody, which is involved in the intraocular inflammation cascade, being effective in suppressing uveitis, allowing a significant reduction in the immunosuppression burden and associated corticosteroid dosage. In this study, we performed a meta-analysis with the aim of evaluating the effectiveness of using ADA in the treatment of non-infectious intermediate and posterior uveitis and panuveitis. A systematic literature review study that addressed research published between 2016 and 2021. Our systematic review selected a total of 60 articles and, among these, 12 were used with different methodological approaches, with age groups and samples varied populations. Within our study, all 12 selected articles demonstrated, in general, a good efficacy and safety of biological therapy with ADA, mainly in combined therapy and aimed at the chronicity and refractoriness of the disease associated with evidence on a pattern of improvement in all or most of the outcomes assessed.
References
Airody, A., Heath, G., Lightman, S. & Gale, R. (2016). Non-infectious uveitis: optimising the therapeutic response. Drugs, 76(1), 27–39.
Balevic, S. J. & Rabinovich, C. E. (2016). Profile of adalimumab and its potential in the treatment of uveitis. Drug Des Devel Ther,10(3), 2997–3003.
Bravo-Ljubetic, L., Peralta-Calvo, J., Noval, S., Pastora-Salvador, N., Abelairas-Gómez, J. & Merino, R. (2013). Adalimumab therapy for refractory childhood uveitis. J AAPOS, 17(5), 456–59.
Burmester, G. R., Panaccione, R., Gordon, K. B., McIlraith, M. J. & Lacerda, A. P. (2013). Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis,72 (4), 517–24.
Diaz-Llopis, M., García-Delpech, S., Salom, D., Udaondo, P., Hernández-Garfella, M., Bosch-Morell, F.& Romero, F. J. (2008). Adalimumab therapy for refractory uveitis: a pilot study. Journal of Ocular Pharmacology and Therapeutics, 24(3), 351-61.
Dobner, B. C., Max, R., Becker, M. D., Heinz, C., Veltrup, I., Heiligenhaus, A. & Mackensen, F. (2013). A three-centre experience with adalimumab for the treatment of non-infectious uveitis. British Journal of Ophthalmology, 97(2), 134-38.
Do Nascimento, H. M. (2016). Uveítes: revisitando o tema. e-Oftalmo. CBO: Revista Digital de Oftalmologia, 2(1).
Durrani, K., Kempen, J. H. & Ying, G. S. (2014). Adalimumab for ocular inflammation. Ocul Immunol Inflamm,10(3), 1–8.
García-De-Vicuña, C., Díaz-Llopis, M. & Salom, D. (2013). Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm, 20(3), 560–632.
Interlandi, E., Leccese, P., Olivieri, I. & Latanza, L. (2014). Adalimumab for treatment of severe Behçet’s uveitis: a retrospective long-term follow-up study. Clin Exp Rheumatol, 32(4), 58–62.
Kunimi, K., Usui, Y., Tsubota, K., Kezuka, T. & Goto, H. (2021). Intraocular surgery under adalimumab therapy in patients with refractory uveitis: a single center study of 23 eyes. Jpn J Ophthalmol. https://doi: 10.1007/s10384-021-00871-3.
Magli, A., Forte, R. & Navarro, P. (2013). Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol, 251 (6),1601–606.
Mattos, P.C. (2015). Tipos de revisão de literatura. Unesp, 1-9.
Mercier, A. E., Ribeiro, E., Korobelnik, J. F., Delyfer, M. N. & Rougier, M. B. (2018). Efficacy of anti-TNF-α therapy for the treatment of non-infectious uveitis: a retrospective study of 21 patients. Ocular Immunology and Inflammation, 26(3), 477-84.
Ming, S., Xie, K., He, H., Li, Y. & Lei, B. (2018). Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review. Drug design, development and therapy, 2005-16.
Muñoz-Gallego, A., Barral, E., Enríquez, E., Tejada, P., Barceló, A. & Inocencio, J. (2017). Adalimumab for the treatment of refractory noninfectious paediatric uveitis. International Ophthalmology, 37, 719-25.
Norcia, L. F., Kiappe, O. P. & Jorge, E. C. (2021). Biological Therapy in Noninfectious Pediatric Uveitis: A Systematic Review. Clin Ophthalmol, https://doi: 10.2147/OPTH.S322445.
Nussenblatt, R. B. (1990). The natural history of uveitis. Int Ophthalmol, 14(5-6), 303–8.
Rother, E. T. (2017). Revisão sistemática x revisão narrativa. Scielo Brasil, 20(2),105-107.
Rudwaleit, M., Rødevand, E. & Holck, P. (2009). Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis,68(5), 696–701.
Schwartzman, S. & Schwartzman, M. (2015). The use of biologic therapies in uveitis. Clin Rev Allergy Immunol, 49(3), 307-16.
Sen, E. S., Sharma, S., Hinchcliffe, A., Dick, A. D. & Ramanan, A. V. (2012). Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease — a case cohort interventional study. Rheumatology, 51(12), 2199-203.
Simonini, G., Taddio, A., Cattalini, M., Caputo, R., De Libero, C., Naviglio, S. & Cimaz, R. (2011). Prevention of flare recurrences in childhood‐refractory chronic uveitis: an open‐label comparative study of adalimumab versus infliximab. Arthritis care & research, 63(4), 612-18.
Suhler, E. B., Adán, A., Brézin, A. P., Fortin, E., Goto, H., Jaffe, G. J. & Dick, A. D. (2018). Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology, 125(7), 1075-87.
Suhler, E. B., Lowder, C. Y. & Goldstein, D. A. (2013). Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol, 97(4), 481–86.
Vallet, H., Seve, P. & Biard, L. (2016). French Uveitis Network. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network. Arthritis Rheumatol, 68(6), 1522–30.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Liana Andrade Oliveira ; Larissa Albuquerque Oliveira; Leticia Fernandes Barroso; Alexis Galeno Matos
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
